Interestingly, the acute phase protein PTX3 levels did not correlate with any of the immune markers studied (Table 1), suggesting that PTX3 might follow different pathways of activation in CRC patients compared to other immune mediators. Here, PTX3 is linked to colorectal carcinoma.